The FDA granted breakthrough device designation to the ACR-368 OncoSignature assay for the identification of patients with ovarian cancer who may derive benefit from the CHK1/2 inhibitor ACR-368.
The FDA has granted fast track designations to ACR-368 monotherapy for the treatment of patients with platinum-resistant ovarian cancer and endometrial cancer who are positive for predicted sensitivity to the agent using Acrivon Therapeutics’ OncoSignature® test.
WATERTOWN, Mass., March 28, 2023 Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors. | March 28, 2023
Akoya (AKYA) Partners with Acrivon for Development of Acrivon s Proprietary OncoSignature Test streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The trial will enroll patients with ovarian, endometrial, and urothelial cancer, and stratify them for treatment using Acrivon's OncoSignature proteomic diagnostic.